TIlmicosin, which is part of the drug, is a semi-synthetic macrolide antibiotic with a broad spectrum of action.
The drug is active against gram-positive (Staphylococcus spp., Streptococcus spp., Corynebacterium spp.), gram-negative microorganisms (Pasteurella spp., Haemophilus spp., Bordetella bronchiseptica, Ornithobacterium rhinotracheale, Actinobacillus pleuropneumonia, Brachyspira hyodysenteriae, Mannheimia haemolytica), actinomycetes (Actinomyces pyogenes) and mycoplasmas (Mycoplasma spp.).
The mechanism of antimicrobial action consists of blocking protein synthesis in the microbial cell at the ribosome level.
The drug is well absorbed from the gastrointestinal tract when administered orally and penetrates into all organs and tissues of the body, primarily into the tissues of the respiratory system, and accumulates in alveolar macrophages. After 2-3 hours, tilmicosin reaches its maximum level in the blood serum, moderately binds to plasma proteins (less than 30%), therapeutic concentrations are maintained in the body for 24 hours.
Tilmicosin is excreted from the body mainly unchanged, mostly with bile and feces, and partly with urine. In case of liver and kidney dysfunction, the excretion period may increase.